Literature DB >> 15269253

Overexpression of glial cell line-derived neurotrophic factor using a lentiviral vector induces time- and dose-dependent downregulation of tyrosine hydroxylase in the intact nigrostriatal dopamine system.

Biljana Georgievska1, Deniz Kirik, Anders Björklund.   

Abstract

The effects of continuous glial cell line-derived neurotrophic factor (GDNF) overexpression in the intact nigrostriatal dopamine (DA) system was studied using recombinant lentiviral (rLV) vector delivery of GDNF to the striatum or substantia nigra (SN) in the rat. Intrastriatal delivery of rLV-GDNF resulted in significant overexpression of GDNF in the striatum (2-4 ng/mg tissue) and anterograde transport of GDNF protein to the SN. Striatal rLV-GDNF delivery initially induced an increase in DA turnover (1-6 weeks), accompanied by significant contralateral turning in response to amphetamine, suggesting an enhancement of the DA system on the injected side. Starting 6 weeks after continuous GDNF delivery, we observed a selective downregulation of tyrosine hydroxylase (TH) protein (approximately 70%) that was maintained until the end of the experiment (24 weeks). A similar effect was observed when rLV-GDNF was injected into the SN. The magnitude of TH downregulation was related to the level of GDNF expression and was most pronounced in animals in which the striatal GDNF level exceeded 0.7 ng/mg tissue. The decreased TH protein levels were associated with similar reductions in the in vitro TH enzyme activity (approximately 70%); however, in vivo L-3,4-dihydroxyphenylalanine production rate and DA tissue levels were maintained at normal levels. The results indicate that downregulation of TH protein reflects a compensatory effect in response to continuous GDNF stimulation of the DA neurons mediated by a combination of overactivity at the DA synapse and a direct GDNF-induced action on TH gene expression. This compensatory mechanism is proposed to maintain long-term DA neuron function within the normal range.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15269253      PMCID: PMC6729873          DOI: 10.1523/JNEUROSCI.1122-04.2004

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  42 in total

1.  Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease.

Authors:  G W Miller; J D Erickson; J T Perez; S N Penland; D C Mash; D B Rye; A I Levey
Journal:  Exp Neurol       Date:  1999-03       Impact factor: 5.330

2.  Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease.

Authors:  J H Kordower; M E Emborg; J Bloch; S Y Ma; Y Chu; L Leventhal; J McBride; E Y Chen; S Palfi; B Z Roitberg; W D Brown; J E Holden; R Pyzalski; M D Taylor; P Carvey; Z Ling; D Trono; P Hantraye; N Déglon; P Aebischer
Journal:  Science       Date:  2000-10-27       Impact factor: 47.728

3.  Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease.

Authors:  N Déglon; J L Tseng; J C Bensadoun; A D Zurn; Y Arsenijevic; L Pereira de Almeida; R Zufferey; D Trono; P Aebischer
Journal:  Hum Gene Ther       Date:  2000-01-01       Impact factor: 5.695

4.  Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model.

Authors:  C Rosenblad; D Kirik; A Björklund
Journal:  Exp Neurol       Date:  2000-02       Impact factor: 5.330

5.  GDNF acutely modulates excitability and A-type K(+) channels in midbrain dopaminergic neurons.

Authors:  F Yang; L Feng; F Zheng; S W Johnson; J Du; L Shen; C P Wu; B Lu
Journal:  Nat Neurosci       Date:  2001-11       Impact factor: 24.884

6.  Effects of intra-striatal GDNF on motor coordination and striatal electrophysiology in aged F344 rats.

Authors:  K E Bowenkamp; L Ujhelyi; E J Cline; P C Bickford
Journal:  Neurobiol Aging       Date:  2000 Jan-Feb       Impact factor: 4.673

7.  In vivo protection of nigral dopamine neurons by lentiviral gene transfer of the novel GDNF-family member neublastin/artemin.

Authors:  C Rosenblad; M Grønborg; C Hansen; N Blom; M Meyer; J Johansen; L Dagø; D Kirik; U A Patel; C Lundberg; D Trono; A Björklund; T E Johansen
Journal:  Mol Cell Neurosci       Date:  2000-02       Impact factor: 4.314

Review 8.  Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model.

Authors:  A Björklund; D Kirik; C Rosenblad; B Georgievska; C Lundberg; R J Mandel
Journal:  Brain Res       Date:  2000-12-15       Impact factor: 3.252

9.  Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system.

Authors:  D Kirik; C Rosenblad; A Bjorklund; R J Mandel
Journal:  J Neurosci       Date:  2000-06-15       Impact factor: 6.167

10.  Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor.

Authors:  D Kirik; C Rosenblad; A Björklund
Journal:  Eur J Neurosci       Date:  2000-11       Impact factor: 3.386

View more
  48 in total

1.  Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: a therapeutic strategy for Parkinson's disease.

Authors:  Kc Biju; Qing Zhou; Guiming Li; Syed Z Imam; James L Roberts; William W Morgan; Robert A Clark; Senlin Li
Journal:  Mol Ther       Date:  2010-06-08       Impact factor: 11.454

2.  The vesicular glutamate transporter-1 upstream promoter and first intron each support glutamatergic-specific expression in rat postrhinal cortex.

Authors:  Guo-rong Zhang; Xu Li; Haiyan Cao; Hua Zhao; Alfred I Geller
Journal:  Brain Res       Date:  2010-12-21       Impact factor: 3.252

3.  Transgene expression in the striatum following intracerebral injections of DNA nanoparticles encoding for human glial cell line-derived neurotrophic factor.

Authors:  A M Fletcher; T H Kowalczyk; L Padegimas; M J Cooper; D M Yurek
Journal:  Neuroscience       Date:  2011-08-04       Impact factor: 3.590

Review 4.  Human gene therapy and imaging in neurological diseases.

Authors:  Andreas H Jacobs; Alexandra Winkler; Maria G Castro; Pedro Lowenstein
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-12       Impact factor: 9.236

5.  Anatomical basis of glial cell line-derived neurotrophic factor expression in the striatum and related basal ganglia during postnatal development of the rat.

Authors:  Tinmarla Frances Oo; Vincent Ries; Jinwhan Cho; Nikolai Kholodilov; Robert E Burke
Journal:  J Comp Neurol       Date:  2005-03-28       Impact factor: 3.215

Review 6.  Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS.

Authors:  Seung T Lim; Mikko Airavaara; Brandon K Harvey
Journal:  Pharmacol Res       Date:  2009-10-17       Impact factor: 7.658

7.  Novel Focused Ultrasound Gene Therapy Approach Noninvasively Restores Dopaminergic Neuron Function in a Rat Parkinson's Disease Model.

Authors:  Brian P Mead; Namho Kim; G Wilson Miller; David Hodges; Panagiotis Mastorakos; Alexander L Klibanov; James W Mandell; Jay Hirsh; Jung Soo Suk; Justin Hanes; Richard J Price
Journal:  Nano Lett       Date:  2017-05-18       Impact factor: 11.189

8.  Nigral GFRα1 infusion in aged rats increases locomotor activity, nigral tyrosine hydroxylase, and dopamine content in synchronicity.

Authors:  Brandon S Pruett; Michael F Salvatore
Journal:  Mol Neurobiol       Date:  2013-01-16       Impact factor: 5.590

9.  Glial cell line-derived neurotrophic factor reverses ethanol-mediated increases in tyrosine hydroxylase immunoreactivity via altering the activity of heat shock protein 90.

Authors:  Dao-Yao He; Dorit Ron
Journal:  J Biol Chem       Date:  2008-03-14       Impact factor: 5.157

10.  AAV2-mediated gene transfer of GDNF to the striatum of MPTP monkeys enhances the survival and outgrowth of co-implanted fetal dopamine neurons.

Authors:  J D Elsworth; D E Redmond; C Leranth; K B Bjugstad; J R Sladek; T J Collier; S B Foti; R J Samulski; K P Vives; R H Roth
Journal:  Exp Neurol       Date:  2008-02-15       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.